ACOR (ACORDIA) FAMPRIDINE IS NOT A VERY GOOD DRUG EVEN IF IT WORKS AS ADVERTISED

Twitter
LinkedIn
Facebook

The FDA Peripheral and Central Nervous System Drugs Advisory Committee meets today to review ACOR’s Fampridine-SR for improvement of walking in patients with multiple sclerosis .

We have been negative on ACOR from the very beginning of Fampridine saga because even if the drug works as ACOR promotes, it is not a very good drug. Moreover, the number of participants in ACOR studies have been relatively small compared to what we think it should be to fully evaluate the risk of seizures. We also think the studies are flawed in how they measure the walking ability. Measurement of anything in MS patients is subjective at best in the first place.

ACOR is a highly promotional company and fund flows have been consistently positive, therefore we have been reluctant to issue a sell signal.

No matter how FDA review comes out, this stock should be sold short. If the review is positive, consider shorting on spikes up. Our ultimate target is $5.

Subscribe to 'Generate Wealth'

Free Forever

More To Explore

30 Day Free Trial

Cancel within 30 days and you owe nothing

When you take a FREE 30 day trial, you get access to powerful techniques used by billionaires and hedge funds to grow richer. You can continue to use these powerful techniques to grow richer even if you cancel your subscription. You come out ahead by subscribing no matter how you look at it.

A fortune is to be made from AI stocks.
Get the list of 18 AI stocks to grab your share of the profits — no cost to you.

A fortune is to be made from AI stocks.

Get the list of 18 AI stocks to grab your share of the profits.

AI is a $1 Trillion Market

Making A Fortune
In Artificial Intelligence

Golden Age of Artificial Intelligence